Spain's cancer care is at a crossroads! The CCI4EU initiative promises progress, but could it widen the gap for rural and vulnerable communities? Balancing innovation with access is crucial! #CancerCare #HealthcareAccess #Spain #CCI4EU #HealthEquality

Background: Arterial thrombosis is an uncommon complication in cancer patients, often overshadowed by venous thromboembolic events. Its occurrence in patients with solid tumors on active antineoplastic treatment poses a significant clinical challenge.Key clinical question: Given the lack of consensus on the optimal therapy for arterial thrombosis in cancer patients, the best practices for managing an aortic thrombus, and the benefit of low molecular weight heparin (LMWH) must be reviewed.Clinical approach: We present the case of a 70-year-old female with stage IVA lung adenocarcinoma who developed an aortic thrombus during chemo-immunotherapy. The thrombus was successfully treated with LMWH, avoiding further complications, and allowing for the continuation of her cancer therapy.Conclusions: This case highlights the importance of early detection and management of arterial thrombus in cancer patients. LMWH proved effective in resolving the thrombus, underscoring its role in managing such complications.

Oligoprogression in MET Exon 14 skipping (METex14)–mutated non–small cell lung cancer (NSCLC) is clinically challenging, particularly when local therapies are contraindicated. We report the first documented case of a 62‐year‐old man with oligoprogressive METex14‐positive NSCLC who achieved a sustained metabolic response following the addition of docetaxel to ongoing tepotinib therapy after progression on tepotinib monotherapy. Due to prior thoracic irradiation, reirradiation and surgical interventions were deemed not feasible, prompting this systemic combination to maintain MET inhibition while targeting resistant tumor clones. This strategy resulted in a partial metabolic response at the primary lung lesion and a sustained complete metabolic response in an adrenal metastasis. The regimen was generally well tolerated; however, Grade 3 peripheral edema required dose reduction of tepotinib. This case supports the potential role of systemic therapy intensification in METex14‐driven NSCLC, highlighting the therapeutic value of continued MET inhibition beyond disease progression, particularly when local treatment and advanced molecular monitoring such as ctDNA are unavailable. Trial Registration: ClinicalTrials.gov identifier: NCT05439993